Markets
Eli Lilly strikes $2.75 billion pact with Insilico to advance AI-discovered medicines globally
Eli Lilly agreed to a headline $2.75 billion deal with Hong Kong-listed Insilico, including $115 million upfront, to bring AI-developed drug candidates to worldwide markets — a notable step in big pharma’s adoption of AI-driven discovery.
Mar 31, 2026
|
1260
Read